BioMarin Pharmaceutical Inc. (BMRN) PHEARLESS Study to be Delayed Several Months - Morgan Stanley
Tweet Send to a Friend
Morgan Stanley analyst Matthew Harrison reiterated an Equalweight rating and $90.00 price target on BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) after ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
